Analysts' Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)
Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns
Leerink Partners Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Raises Target Price to $55
Express News | Bristol-Myers Squibb: Opdivo in combination with cisplatin chemotherapy approved for first-line treatment of urothelial carcinoma.
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy Right Now?
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo